Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection
Introduction: The emergence of SARS-CoV-2 variants has raised concerns on future vaccine efficacy as most vaccines target only the spike protein. Hence, vaccines targeting multiple SARS-CoV-2 proteins will offer broader protection and improve our preparedness to combat the pandemic. Objectives: The...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-02-01
|
| Series: | Journal of Advanced Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2090123221001417 |
| _version_ | 1818952487863844864 |
|---|---|
| author | Vijayakumar Jawalagatti Perumalraja Kirthika Ji-Young Park Chamith Hewawaduge John Hwa Lee |
| author_facet | Vijayakumar Jawalagatti Perumalraja Kirthika Ji-Young Park Chamith Hewawaduge John Hwa Lee |
| author_sort | Vijayakumar Jawalagatti |
| collection | DOAJ |
| description | Introduction: The emergence of SARS-CoV-2 variants has raised concerns on future vaccine efficacy as most vaccines target only the spike protein. Hence, vaccines targeting multiple SARS-CoV-2 proteins will offer broader protection and improve our preparedness to combat the pandemic. Objectives: The study aimed to develop a novel vaccine strategy by combining a eukaryotic vector expressing multiple SARS-CoV-2 genes and Salmonella-mediated in vivo DNA delivery. Methods: The eukaryotic vector was designed to function as a DNA-launched RNA replicon in a self-replicating and self-amplifying mRNA mechanism. By exploiting the self-cleaving peptide, P2A, we fused four SARS-CoV-2 targets, including receptor-binding domain (RBD), heptad repeat domain (HR), membrane protein (M) and epitopes of nsp13, in a single open reading frame. Western blot and immunofluorescence assays were used to determine protein expression. In mice, the vaccine's safety and immunogenicity were investigated. Results: Western blot analysis revealed co-expression all four proteins from the vaccine construct, confirming the efficiency of Salmonella-mediated gene delivery and protein expression. The vaccine candidate was safe and elicited robust antigen-specific antibody titers in mice, and a recall response from splenocytes revealed induction of strong cell-mediated immunity. Flow cytometry demonstrated an increase in sub-populations of CD4+ and CD8+ T cells with the highest CD4+ and CD8+ T cells recorded for HR and RBD, respectively. Overall, humoral and cellular immune response data suggested the induction of both Th1 and Th2 immunity with polarization towards an antiviral Th1 response. We recorded a potent SARS-CoV-2 neutralizing antibody titers in the immunized mice sera. Conclusions: The Salmonella bactofection ensured optimum in vivo gene delivery, and through a P2A-enabled efficient multicistronic expression, the vaccine candidate elicited potent anti-SARS-CoV-2 immune responses. These findings provide important insight into development of an effective multivalent vaccine to combat SARS-CoV-2 and its variants. |
| first_indexed | 2024-12-20T09:51:10Z |
| format | Article |
| id | doaj.art-98d37cd8f49c425d8dfef7d1ece6bf98 |
| institution | Directory Open Access Journal |
| issn | 2090-1232 |
| language | English |
| last_indexed | 2024-12-20T09:51:10Z |
| publishDate | 2022-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Advanced Research |
| spelling | doaj.art-98d37cd8f49c425d8dfef7d1ece6bf982022-12-21T19:44:35ZengElsevierJournal of Advanced Research2090-12322022-02-0136211222Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofectionVijayakumar Jawalagatti0Perumalraja Kirthika1Ji-Young Park2Chamith Hewawaduge3John Hwa Lee4Department of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan Campus, 54596, Republic of KoreaDepartment of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan Campus, 54596, Republic of KoreaDepartment of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan Campus, 54596, Republic of KoreaDepartment of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan Campus, 54596, Republic of KoreaCorresponding author.; Department of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan Campus, 54596, Republic of KoreaIntroduction: The emergence of SARS-CoV-2 variants has raised concerns on future vaccine efficacy as most vaccines target only the spike protein. Hence, vaccines targeting multiple SARS-CoV-2 proteins will offer broader protection and improve our preparedness to combat the pandemic. Objectives: The study aimed to develop a novel vaccine strategy by combining a eukaryotic vector expressing multiple SARS-CoV-2 genes and Salmonella-mediated in vivo DNA delivery. Methods: The eukaryotic vector was designed to function as a DNA-launched RNA replicon in a self-replicating and self-amplifying mRNA mechanism. By exploiting the self-cleaving peptide, P2A, we fused four SARS-CoV-2 targets, including receptor-binding domain (RBD), heptad repeat domain (HR), membrane protein (M) and epitopes of nsp13, in a single open reading frame. Western blot and immunofluorescence assays were used to determine protein expression. In mice, the vaccine's safety and immunogenicity were investigated. Results: Western blot analysis revealed co-expression all four proteins from the vaccine construct, confirming the efficiency of Salmonella-mediated gene delivery and protein expression. The vaccine candidate was safe and elicited robust antigen-specific antibody titers in mice, and a recall response from splenocytes revealed induction of strong cell-mediated immunity. Flow cytometry demonstrated an increase in sub-populations of CD4+ and CD8+ T cells with the highest CD4+ and CD8+ T cells recorded for HR and RBD, respectively. Overall, humoral and cellular immune response data suggested the induction of both Th1 and Th2 immunity with polarization towards an antiviral Th1 response. We recorded a potent SARS-CoV-2 neutralizing antibody titers in the immunized mice sera. Conclusions: The Salmonella bactofection ensured optimum in vivo gene delivery, and through a P2A-enabled efficient multicistronic expression, the vaccine candidate elicited potent anti-SARS-CoV-2 immune responses. These findings provide important insight into development of an effective multivalent vaccine to combat SARS-CoV-2 and its variants.http://www.sciencedirect.com/science/article/pii/S2090123221001417COVID-19VariantVaccineSalmonellaMulticistronic expression |
| spellingShingle | Vijayakumar Jawalagatti Perumalraja Kirthika Ji-Young Park Chamith Hewawaduge John Hwa Lee Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection Journal of Advanced Research COVID-19 Variant Vaccine Salmonella Multicistronic expression |
| title | Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection |
| title_full | Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection |
| title_fullStr | Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection |
| title_full_unstemmed | Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection |
| title_short | Highly feasible immunoprotective multicistronic SARS-CoV-2 vaccine candidate blending novel eukaryotic expression and Salmonella bactofection |
| title_sort | highly feasible immunoprotective multicistronic sars cov 2 vaccine candidate blending novel eukaryotic expression and salmonella bactofection |
| topic | COVID-19 Variant Vaccine Salmonella Multicistronic expression |
| url | http://www.sciencedirect.com/science/article/pii/S2090123221001417 |
| work_keys_str_mv | AT vijayakumarjawalagatti highlyfeasibleimmunoprotectivemulticistronicsarscov2vaccinecandidateblendingnoveleukaryoticexpressionandsalmonellabactofection AT perumalrajakirthika highlyfeasibleimmunoprotectivemulticistronicsarscov2vaccinecandidateblendingnoveleukaryoticexpressionandsalmonellabactofection AT jiyoungpark highlyfeasibleimmunoprotectivemulticistronicsarscov2vaccinecandidateblendingnoveleukaryoticexpressionandsalmonellabactofection AT chamithhewawaduge highlyfeasibleimmunoprotectivemulticistronicsarscov2vaccinecandidateblendingnoveleukaryoticexpressionandsalmonellabactofection AT johnhwalee highlyfeasibleimmunoprotectivemulticistronicsarscov2vaccinecandidateblendingnoveleukaryoticexpressionandsalmonellabactofection |